Free Trial

Novartis (NVS) Competitors

Novartis logo
$117.41 -0.56 (-0.48%)
Closing price 03:59 PM Eastern
Extended Trading
$117.41 +0.00 (+0.00%)
As of 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NVS vs. NVO, AZN, SNY, GSK, TAK, ARGX, ONC, BNTX, SMMT, and INSM

Should you be buying Novartis stock or one of its competitors? The main competitors of Novartis include Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

Novartis vs. Its Competitors

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$50.32B4.93$11.94B$6.8717.09
Novo Nordisk A/S$42.12B7.50$14.64B$3.3820.93

Novartis has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Novartis pays an annual dividend of $2.60 per share and has a dividend yield of 2.2%. Novo Nordisk A/S pays an annual dividend of $1.64 per share and has a dividend yield of 2.3%. Novartis pays out 37.8% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 48.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis currently has a consensus price target of $123.67, indicating a potential upside of 5.33%. Novo Nordisk A/S has a consensus price target of $112.00, indicating a potential upside of 58.33%. Given Novo Nordisk A/S's stronger consensus rating and higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novartis
3 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.00
Novo Nordisk A/S
2 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.27

13.1% of Novartis shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Novo Nordisk A/S has a net margin of 34.52% compared to Novartis' net margin of 25.64%. Novo Nordisk A/S's return on equity of 80.94% beat Novartis' return on equity.

Company Net Margins Return on Equity Return on Assets
Novartis25.64% 41.08% 16.83%
Novo Nordisk A/S 34.52%80.94%24.23%

In the previous week, Novo Nordisk A/S had 21 more articles in the media than Novartis. MarketBeat recorded 47 mentions for Novo Nordisk A/S and 26 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 1.21 beat Novartis' score of 0.93 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novartis
18 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Novo Nordisk A/S
36 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive

Summary

Novo Nordisk A/S beats Novartis on 14 of the 18 factors compared between the two stocks.

Get Novartis News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVS vs. The Competition

MetricNovartisLarge Cap Pharma IndustryMedical SectorNYSE Exchange
Market Cap$249.20B$257.96B$5.70B$21.15B
Dividend Yield2.20%2.81%4.59%3.58%
P/E Ratio17.0927.9327.9027.76
Price / Sales4.935.09442.1958.69
Price / Cash11.0214.1136.5523.00
Price / Book5.9017.978.634.67
Net Income$11.94B$8.49B$3.24B$993.85M
7 Day Performance2.51%3.08%3.22%1.16%
1 Month Performance-1.26%2.96%10.72%4.99%
1 Year Performance7.37%-4.35%34.94%12.54%

Novartis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVS
Novartis
1.8043 of 5 stars
$117.41
-0.5%
$123.67
+5.3%
+9.6%$249.20B$50.32B17.0975,883Earnings Report
NVO
Novo Nordisk A/S
4.331 of 5 stars
$70.42
+0.5%
$112.00
+59.1%
-47.5%$315.63B$42.12B20.9177,349Positive News
AZN
AstraZeneca
3.1416 of 5 stars
$73.90
+1.2%
$89.00
+20.4%
-7.8%$229.37B$54.07B29.7094,300Upcoming Earnings
SNY
Sanofi
3.6507 of 5 stars
$50.21
+0.1%
$61.50
+22.5%
-0.5%$123.25B$44.46B17.9582,878Upcoming Earnings
GSK
GSK
1.7832 of 5 stars
$38.01
-0.1%
$37.38
-1.7%
-2.0%$77.90B$40.10B19.6168,629Upcoming Earnings
Analyst Revision
TAK
Takeda Pharmaceutical
2.1038 of 5 stars
$14.65
-0.6%
N/A+7.9%$46.71B$30.09B66.7347,455Positive News
Upcoming Earnings
ARGX
argenex
3.7289 of 5 stars
$584.58
+1.6%
$728.06
+24.5%
+21.7%$35.67B$2.25B35.961,599Upcoming Earnings
Analyst Forecast
Analyst Revision
ONC
BeOne Medicines
1.4884 of 5 stars
$296.26
+0.5%
$327.56
+10.6%
N/A$32.47B$3.81B-79.6411,000Insider Trade
BNTX
BioNTech
1.4753 of 5 stars
$113.81
-0.7%
$136.58
+20.0%
+34.0%$27.45B$2.98B-33.586,772
SMMT
Summit Therapeutics
3.2163 of 5 stars
$27.88
-0.5%
$34.67
+24.3%
+177.6%$20.71BN/A-82.00110
INSM
Insmed
4.0666 of 5 stars
$103.41
0.0%
$109.20
+5.6%
+36.1%$19.48B$381.03M-17.261,271Positive News
Analyst Forecast
Insider Trade

Related Companies and Tools


This page (NYSE:NVS) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners